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ABSTRACT.
Mitochondrial dysfunction is associated with a variety of human diseases including inherited mitochondrial diseases, neurodegenerative disorders, diabetes mellitus and cancer. Effective medical therapies for mitochondrial diseases will ultimately require an optimal drug delivery system, which will likely be achieved through innovations in the nanotechnology of intracellular trafficking. To achieve efficient mitochondrial drug delivery, two independent processes, i.e., "cytoplasmic delivery through the cell membrane" and "mitochondrial delivery through the mitochondrial membrane" are required. In previous studies, we developed an octaarginine (R8) modified nano-carrier for efficient cytoplasmic delivery, showing that R8-modified liposomes were internalized into cells efficiently. On the other hand, we also constructed MITO-Porter for the mitochondrial delivery of macromolecules, a liposome-based carrier that delivers cargos to mitochondria via membrane fusion. Here, we report the development of a Dual Function MITO-Porter (DF-MITO-Porter), based on the concept of integrating both R8-modified liposomes and MITO-Porter. We show that the DF-MITO-Porter effectively delivers exogenous macrobiomolecules into the mitochondrial matrix, and provide a demonstration of its potential use in therapies aimed at mitochondrial DNA.
INTRODUCTION
Mitochondrial dysfunction is implicated in a variety of human diseases including mitochondrial inherited diseases, neurodegenerative disorders, diabetes mellitus and cancer. [1] [2] [3] [4] [5] [6] [7] [8] [9] Effective medical therapies for such diseases will ultimately require an optimal drug delivery system, which will likely be achieved through innovations in the nanotechnology of intracellular trafficking. In addition, the use of therapeutic agents will be needed to overcome the impregnable mitochondrial membrane to exert pharmacological effects inside mitochondria. Previous studies reported that the conjugation of mitochondrial targeting signal peptides to exogenous proteins and small linear DNAs enhanced their delivery to mitochondria, 10, 11 but this strategy failed, in cases of macromolecules and hydrophobic molecules, including mitochondrial DNA and proteins. [12] [13] [14] To achieve efficient mitochondrial drug delivery, two independent processes i.e., "cytoplasmic delivery through the cell membrane" and "mitochondrial delivery through the mitochondrial membrane" are required. 6 In previous studies, we reported on the development of an octaarginine (R8) modified nano-carrier for efficient cytoplasmic delivery 15, 16 and a MITO-Porter for the mitochondrial delivery of macromolecules. 17 The former, R8 18, 19 is a synthetic peptide that mimics the trans-activating transcriptional activator (TAT) derived from the human immunodeficiency virus. 20, 21 We showed that high-density R8-modified liposomes were internalized primarily via macropinocytosis and are efficiently delivered to the cytosol, similar to an adenovirus vector. 15, 16 On the other hand, we proposed a MITO-Porter, which is different from mitochondrial targeting signal peptide system, for mitochondrial delivery. 17 The MITO-Porter is a liposome-based nano-carrier that delivers cargos to mitochondria via membrane fusion. Using the green fluorescence protein as a model macromolecule and analysis by confocal laser scanning microscopy (CLSM), we were able to confirm mitochondrial macromolecule delivery by the MITO-Porter. We were also able to verify that the MITO-Porter delivered cargoes to the mitochondrial matrix, which pools mitochondrial DNA (mtDNA), using this novel imaging method.
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A nano-carrier system which achieves both efficient cytoplasmic delivery and mitochondrial macromolecule delivery could open new avenues for mitochondrial disease therapies. We report herein on the development of a Dual Function MITO-Porter (DF-MITO-Porter), which has the potential for serving as a nano-device for mitochondrial disease therapies, based on the concept integrating both high-density R8-modified liposomes and the conventional MITO-Porter (Fig. 1) . The critical structural elements of the DF-MITO-Porter include a complexed particle of cargos that are coated with two mitochondria-fusogenic inner membranes and two endosome-fusogenic outer membranes. Modification of the outer envelope-surface with a high density of R8 18, 19 greatly assists in the efficient internalization of the carriers into cells (1st step). Inside the cell, the carrier escapes from the endosome into the cytosol via membrane fusion, a process that is mediated by the outer endosome-fusogenic lipid membranes (2nd step). The carrier then binds to mitochondria via R8 (3rd step) and fuses with the mitochondrial membrane (4th step). Recent studies reported that TAT has the ability to deliver a certain cargo to mitochondria, 23, 24 and we also showed that modification of the liposome-surface with R8 significantly enhances binding to mitochondria, regardless of the lipid composition. 6 Thus, we chose R8, not only as a cytoplasmic delivery device but as a mitochondrial targeting device as well.
In this study, we attempted to prepare DF-MITO-Porter with mitochondria-fusogenic inner membranes and endosome-fusogenic outer membranes, and optimize the characteristics. Intracellular observation using CLSM permitted us to compare mitochondrial targeting activity between DF-MITOPorter and conventional MITO-Porter. Moreover, we validated that DF-MITO-Porter delivered exogenous macro-biomolecules into mitochondria matrix. Finally, we screened the optimal lipid composition for the DF-MITO-Porter, for achieving a high mitochondrial membrane fusion activity and low cytotoxicity.
RESULTS

Construction of DF-MITO-Porter
The findings reported herein, confirm that the DF-MITO-Porter has the ability to deliver macromolecules into the mitochondrial matrix, which pools mtDNA, over the mitochondrial doublemembrane structure. DNase I protein was chosen as a model macromolecule, which permitted us to estimate mitochondrial matrix delivery of the carrier. It was expected that mtDNA would be digested, when the mitochondrial matrix delivery of DNase I progressed. The construction of the DF-MITOPorter encapsulating DNase I requires the following three steps (Fig. 2a): (1) the construction of nano particles containing DNase I; (2) coating the nano particles with mitochondria-fusogenic envelope; (3) further coating endosome-fusogenic envelope in a step-wise manner, based on our previous report regarding gene packaging with two-different types of lipid layers. 25 We first determined the optimal conditions for complexation between DNase I protein (M.W. 36 kDa, weak negative charge) and stearyl R8 (STR-R8) 26 that would be suitable for the complexation of proteins. 27 We mixed DNase I with STR-R8 at several complex-inducer/protein (C/P) molar ratios to form nano-particles and then determined their diameters and ζ-potentials (surface charges) (Figs. 2b,c) .
Figure 2b
shows data for the diameters of the complexes. Particles with diameters of less than 200 nm were formed at C/P molar ratios higher than 10. Figure 2c shows the ζ potentials for the complexes.
The charges of the particles were changed from minus to plus with increasing C/P ratios. In this study, we chose small positively charged particles formed at a C/P molar ratio of 10 for preparation of the DF-MITO-Porter. We also prepared small unilamellar vesicles (SUVs) with various lipid compositions ( Table S1 ). The positively charged particles were then coated with the first two-layered envelope by the assembly of negatively charged SUVs. The resulting structure was modified with STR-R8 to reverse the surface charge, and then coated with the second envelope via the fusion of negatively charged SUVs.
Finally, the carrier-surface was modified with STR-R8 to give the final DF-MITO-Porter, which is a tetra-lamellar structured nano particle. was used in the control inner envelope. As shown in Fig 2d, the prepared carriers were positively charged nano particles with a homogeneous structure. We also prepared a conventional MITO-Porter for purposes of checking the multi-layered structure value ( Figure S1 ).
Intracellular observation of DF-MITO-Porter using confocal laser scanning microscopy and evaluation for mitochondrial targeting activity
We observed the intracellular trafficking of the DF-MITO-Porter and the conventional MITOPorter using CLSM to validate that the carrier was able to regulate its intracellular trafficking for efficient mitochondrial delivery. In the case of the DF-MITO-Porter, many yellow clusters were observed ( Fig. 3a) , indicating that the NBD-DOPE in the carriers (green) are co-localized with mitochondria (stained red with MitoFluor Red 589). Moreover, it was confirmed that the DF-MITOPorter accumulated in mitochondria more efficiently compared to the conventional MITO-Porter ( Consequently, the fraction of mitochondrial targeted positive cells of the DF-MITO-Porter (more than 80 %) was considerably higher than the corresponding value for the conventional MITO-Porter (Fig. 4c) .
This suggests that a multi-layered structure can be very useful for mitochondrial delivery in living cells.
Relationship between mitochondrial membrane fusion activity and cytotoxicity
The possibility that the DF-MITO-Porter might induce cytotoxicity cannot be excluded, since this system fuses with the mitochondria, which play a role in the homeostasis of vital physiological functions. Therefore, we investigated the relationship between mitochondrial membrane fusion activity and cytotoxicity. In this experiment, we prepared an empty DF-MITO-Porter with various inner mitochondria-fusogenic envelopes as previously reported, 17 and then evaluated their cell viabilities. The graph in Fig. 5 shows the relationship between mitochondrial membrane fusion activity (x-axis) and cell viability (y-axis). We also calculated Pearson's correlation coefficient (r = 0.21), and determined if the correlation coefficient was significantly different from zero using a t-test (p > 0.05). We did not find a significant correlation between mitochondrial membrane fusogenic activity and cell viability. These results suggest that a high fusogeinic activity with the mitochondrial membrane induces cytotoxicity is not universally true. The finding that a carrier with an inner envelope composed of SM was optimal for the DF-MITO-Porter is particularly noteworthy, since it has a high mitochondrial membrane fusogenic activity but low cytotoxicity.
Evaluation of mtDNA-levels after the mitochondrial delivery of DNase I using the DF-MITOPorter
To validate the conclusion that the DF-MITO-Porter is useful as a carrier of therapeutic cargos, we examined the delivery of DNase I protein to the mitochondrial matrix, since the latter is an active bio-molecule that functions inside mitochondria. In a previous study, we reported on the successful mitochondrial matrix delivery of the MITO-Porter, as evidenced by the use of our novel imaging method. 22 In the paper, we used propidium iodide (PI), a membrane-impermeable red-fluorescent dye for staining nucleic acids as an aqueous phase marker for the MITO-Porter. This dye permits mitochondrial matrix delivery to be confirmed, by the detection of red-fluorescent light, because the light is emitted as the result of the conjugation of the dye with mtDNA in the mitochondrial matrix. We first confirmed mitochondrial matrix delivery in isolated rat liver mitochondria using the MITO-Porter.
CLSM analyses showed that this system can be used to efficiently visualize mtDNA, not only in isolated mitochondria, but in living cells as well. We also verified that no red-fluorescent light was produced when PI only was incubated with isolated mitochondria or living cells, indicating that PI did not gain access to mtDNA inside mitochondrial matrix. Finally, the fact that the red fluorescence could be detected in living cells in spectral imaging fluorescent microscopy experiments clearly demonstrated that the MITO-Porter successfully delivered its cargo to the mitochondrial matrix. Based on our previous report, we conclude that the DF-MITO-Porter has the ability to deliver cargoes to the mitochondrial matrix.
To verify that mtDNA-levels were decreased after the mitochondrial delivery of DNase I using the DF-MITO-Porter, we evaluated mtDNA-levels within cells using PCR. DNase I protein encapsulated in carriers were incubated with HeLa cells. The cellular DNA was then purified and subjected to the PCR. PCR assays to detect the ND6 and β-Actin genes were performed in order to detect both mtDNA and nuclear DNA. The primers used in these experiments are summarized in Table   S2 . Figure 6 shows agarose gel electrophoresis data for the PCR products derived from mtDNA ( Fig. 6a ) and nuclear DNA (Fig. 6b) . In the case of the DF-MITO-Porter, decreases in mtDNA-levels were observed (lanes 4, 5 in Fig. 6a ), whereas carriers with a low mitochondrial fusion activity had a negligible effect on mtDNA-levels (lane 3 in Fig. 6a ). This result suggests that DNase I is delivered to mitochondria by the DF-MITO-Porter, as indicated by the digestion of mtDNA by DNase I to some extent. On the other hand, a decrease in nuclear DNA-levels was not detected in any of the carriers (Fig.   6b) . Moreover, we quantified mtDNA-levels within the cells using real-time PCR (Fig. 6c) . The results
showed that the DF-MITO-Porter decreased mtDNA-levels compared with carriers with a low mitochondrial fusion activity. We also confirmed that the MITO-Porter has a high fusogenic activity for mitochondria, but that is failed to effectively fuse with the nucleus (data not shown). Based on these results, it is presumed that the mitochondrial specific fusion activity of the MITO-Porter might be involved in a pathway related to the selective digestion of mtDNA.
DISCUSSION
In this study, we attempted to achieve macromolecule packaging using a multifunctional envelope-type nano-device (MEND) preparation technique. The MEND consists of a condensed pDNA core and a lipid envelope equipped with various functional devices that mimic envelope-type viruses 29, 30 .
The condensation of pDNA into a compact core prior to its inclusion in the lipid envelope has several advantages as follows: protection of pDNA from DNase; size control; and, improved packaging efficiency resulting from electrostatic interactions between the condensed core and the lipid envelope.
To date, we have been successful in efficiently packaging not only pDNA, but also oligo nucleic acids, proteins and other substances into a MEND 27, [31] [32] [33] . On the other hand, the MITO-Porter system delivers cargos into mitochondria via a membrane fusion mechanism. Therefore, large cargoes could be delivered to mitochondria, provided that the cargoes can be encapsulated in the MITO-Porter.
Accordingly, a combination of a MITO-Porter and a macromolecule packaging technique in MEND preparations would likely achieve the mitochondrial delivery of macromolecules such as pDNA, mtDNA, oligo nucleic acids and proteins.
We constructed the DF-MITO-Porter according to Fig. 2a , using the multi-layering method 24 .
First, a di-lamellar structured nano particle (D-SNP) was prepared through membrane fusion of neighboring SUVs, triggered by the assembly of negatively charged SUVs around the positively charged complexed nano-particle of DNase I protein. As previously proposed, it is possible that core particles can form a di-lamellar structure during liposome incubation. 34 The surface of the resulting particles is then modified with STR-R8 to reverse the surface charge. Next, R8-modified D-SNP was coated with the second envelope, again through the fusion of negatively charged SUV to produce T-SNP. If the 2nd SUVs (~60 nm) only bind to the D-SNP (~140 nm), the mean diameter would be expected to be approximately 260 nm. However, the resulting particle had a diameter of ~150 nm, suggesting that the 2nd SUVs fuse with each other, forming a T-SNP. The conversion of ζ potential in each coating process strongly suggests that the complexed nano-particles of DNase I protein underwent a step-wise encapsulation. Thus, the resulting DF-MITO-Porter consists of two types of lipid layers. We applied the confocal image-assisted three-dimensionally integrated quantification (CIDIQ) method to evaluate the fraction of mitochondrial targeted positive cells 35, 36 and counted number of suggesting that a multi-layered structure can be very useful for improving mitochondrial delivery.
Mitochondrial delivery requires the regulation of many intracellular trafficking steps. In this study, we attempted to improve endosomal escape using a multi-layered structure with endosomal fusogenic activity. As a result, the DF-MITO-Porter could deliver molecules to mitochondria more efficiently than a conventional carrier. However, it would be difficult to achieve selective mitochondrial delivery using the current DF-MITO-Porter. On the other hand, the conjugation of mitochondrial targeting signal peptides can achieve selective mitochondrial delivery, 10,11 but this strategy fails, in cases of macromolecules and hydrophobic molecules. [12] [13] [14] In the future, we plan to integrate mitochondrial targeting signal peptides and a MITO-Porter system to achieve the selective delivery of macromolecules to mitochondria. Studies concerning this are currently in progress.
The DF-MITO-Porter developed in this study, is an innovative nano-device for mitochondrial delivery, which has the ability to pass through endosomal and mitochondrial membranes via step-wise membrane fusion. The findings show that the DF-MITO-Porter delivers exogenous macro-biomolecules into the mitochondrial matrix. Moreover, we identified the optimal lipid composition for the DF-MITOPorter, for achieving a high mitochondrial membrane fusion activity and low cytotoxicity. Our ultimate goal is to develop a mitochondrial drug delivery system, not only effective cargo delivery, but also a system that will be functional inside a mitochondrion for therapy. Future studies will involve attempts to improve the DF-MITO-Porter in terms of mitochondrial gene function with experts in the field of mitochondrial molecular biology. Studies directed toward this goal are currently in progress.
MATERIALS AND METHODS
Materials
Cholesterol (Chol), 1,2-dioleoyl-sn-glycero-3-phosphatidyl ethanolamine (DOPE), 7-nitrobenz- 
Preparation of complexed protein particles with STR-R8
DNase I protein was gently mixed with the STR-R8, as complex-inducer, in 100 l of 10 mM HEPES buffer (HB, pH 7.4), followed by incubation for 15 min at 25ºC to form complexed protein particles. Particles of the DNase I/STR-R8 were formed using 50 g of DNase I and STR-R8 in a series of molar ratios of complex-inducer/protein (C/P).
Construction of DF-MITO-Porter
The DNase I-encapsulated Dual Function MITO-Porter (DF-MITO-Porter) was constructed by the multi-layering method (Fig. 2a) , as previously reported. 25 A solution of DNase I protein in HB (1 mg/ml) was mixed with an STR-R8 solution to form complexed protein particles by gently pipetting at a C/P molar ratio of 10, followed by incubation for 15 min at 25ºC. For inner and outer envelopes, various SUVs were prepared. The suspended negatively charged SUVs and complexed protein particles were mixed at a ratio of 3 : 1 (v/v) to coat the complexed protein particles with a double-lipid envelope to produce a di-lamellar structured nano particle (D-SNP). These SUVs composed of mitochondriafusogenic lipid [DOPE/PA = 9 : 2, DOPE/SM/CHEMS = 9 : 2 : 1 (molar ratio)] or non-fusogenic lipid
[EPC/CHEMS = 9 : 2 (molar ratio)]. An STR-R8 solution (10 mol% of total lipid) was added to the suspension of D-SNPs to reverse the surface charge. This suspension was then mixed with endosomefusogenic SUV [DOPE/PA = 7 : 2 (molar ratio)] at a ratio of 1 : 2 (v/v) to generate particles with a double endosome-fusogenic envelope, hereafter referred to a tetra-lamellar structured nano particle (T-SNP). The STR-R8 solution (10 mol% of endosome-fusogenic lipid) was added to the suspension of T-SNP to modify the outer envelope with R8. We refer to the R8 modified T-SNP with mitochondriafusogenic inner envelope that contain PA and SM as the DF-MITO-Porter (PA) and the DF-MITOPorter (SM), respectively.
Measurement of diameter and ζ potential
Particle-diameter was measured by a quasi-elastic light scattering method and ζ potentials were determined electrophoretically by means of an electrophoretic light scattering spectrophotometer (Zetasizer Nano ZS; Malvern Instruments, Herrenberg, Germany). method. 35, 36 The fraction of mitochondrial targeted positive cells was determined as described below.
Intracellular trafficking observation of DF-MITO-Porter using CLSM
First, the yellow pixel areas where carrier (green) co-localized with mitochondria (red) were marked in each xy plane. We define cells where carriers co-localized with mitochondria in at least one Z-series image as mitochondrial targeted positive cells. In some cases, it was difficult to distinguish the localization of the carrier between on and outside the mitochondria. Therefore, criteria were introduced to classify the carrier cluster as co-localized in the mitochondria when more than 50% of the pixels of We prepared a graph showing mitochondrial membrane fusion activity (x-axis) and cell viability (y-axis). For the x-axis, we used data reported in a previous study, 17 where we calculated mitochondrial fusion activities in terms of the cancellation of fluorescent resonance energy transfer and β-Actin (-) were used as shown in Table S2 .
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FIGURE LEGENDS. Table S1 . Lipid composition and property of SUVs.
Small unilamellar vescicles (SUVs) with various lipid compositions were prepared by the following procedure. A 1.5 mL aliquot of 10 mM HEPES buffer (pH 7.4) was applied to 825 nmol of a dried lipid film formed on the bottom of a glass tube. After incubation for 10 min, the suspensions were sonicated for 15 sec using a bath-type sonicator (85 W, Aiwa Co., Tokyo, Japan). The resulting suspensions were then sonicated using a probe-type sonicator ( Table S2 . Primers used in the PCR to evaluate the levels of mtDNA and nuclear DNA.
PCR assays to detect the ND6 and β-actin genes were performed in order to detect mtDNA and nuclear DNA of HeLa cell lysates, respectively. ND6, mitochondrial NADH dehydrogenase 6.
